BIOTRON LIMITED - Investor Presentation 2016

==> picture [227 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: [email protected] Website: www.biotron.com.au

4 May 2016

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(12 pages by email)

Dear Madam

PRESENTATION AT BIOTECH INVEST 2016

I attach a presentation which is being delivered this week by Biotron Limited to the Biotech Invest conferences in Singapore and Hong Kong. Biotech Invest provides a unique opportunity to showcase the Company’s product pipeline and its investment potential to an international audience of investors and potential partners.

As highlighted in the presentation:

Biotron’s lead compound, BIT225, is a first-in-class, novel compound which has been shown to have pan-genotype activity against Hepatitis C (HCV), including hard to treat HCV genotypes 1a, 1b and 3.
China represents a potentially large market with 30 million people reported to be infected with HCV.
BIT225 has also shown clinical efficacy in reducing HIV virus levels in hidden reservoirs which are not sensitive to current anti-HIV drugs and which, if untreated, can lead to chronic life-long infection.
Biotron’s core expertise is in the design and development of drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Yours sincerely

==> picture [95 x 60] intentionally omitted <==

Peter J. Nightingale Company Secretary

pjn8471

Enquiries

Dr Michelle Miller Managing Director Biotron Limited +61-2 9805 0488 +61-(0)412313329

Rudi Michelson Monsoon Communications +61-3 9620 3333

BIOTRON
LIMITED (ASX:BIT)

Singapore
Biotech
Invest
2016 Asia
Biotech
Invest
2016

==> picture [720 x 50] intentionally omitted <==

This
presenta,on
may
contain
forward-‐looking
statements
with
respect
to
the
financial
condi,on, results
and
business
achievements/performance
of
Biotron
Limited
(ACN
086
399
144)
and
certain of
the
plans
and
objec,ves
of
its
management.
These
statements
are
statements
that
are
not historical
facts.
Words
such
as
“should”,
“expects”,
“an,cipates”,
“es,mates”,
“believes”
or
similar expressions,
as
they
relate
to
Biotron
Limited,
are
intended
to
iden,fy
forward-‐looking
statements. By
their
nature,
forward-‐looking
statements
involve
risk
and
uncertainty
because
they
reflect Biotron’s
current
expecta,ons
and
assump,ons
as
to
future
events
and
circumstances
that
may
not prove
accurate.
There
is
no
guarantee
that
the
expected
events,
trends
or
results
will
actually occur.
Any
changes
in
such
assump,ons
or
expecta,ons
could
cause
actual
results
to
differ materially
from
current
expecta,ons.

==> picture [720 x 50] intentionally omitted <==

• Clinical
stage
drug
development
company

Drug
development
plaWorm
for
new
class
of
an,viral
drugs
Phase
2
clinical
programs
for
Hepa,,s
C
virus
(HCV)
and
HIV-‐1
Earlier
stage
programs
include
Dengue,
Influenza
and
others
• Headquartered
in
Sydney,
Australia

INDICATION	COMPOUND	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Hep C	BIT225
HIV-1/Hep C	BIT225
HIV-1	BIT225
Next gen – Hep C	BIT314
Dengue, Infuenza	Leads

==> picture [720 x 50] intentionally omitted <==

**Biotron’s

Core
Technology**

Designed library of compounds to target viroporins: IniZally >250 compounds design~~ed~~ ~~and~~ ~~synthesised;~~ librarynow ~350 BIT314 (HCV) Compounds screened in proprietary assay set up for each virus target e.g. HIV-1 Vpu; HCV p7; Infuenza M2; Dengue M; Coronavirus E. Hits tested against ~~virus~~ ~~in~~ ~~cell~~ cultures Lead op,misa,on and selec,on OTHER “HITS” IN LIBRARY include: - Infuenza A and B - Coronaviruses ~~-~~ ~~Including~~ ~~SARS~~ - Epstein-Barr virus(EBV) - HepaZZs B virus (HBV) BIT225 is a representaZon of the value that resides within Biotron’s core experZse DENGUE – ~~Several~~ compounds with promising anZviral acZvity OTHERVIRUSES – Secondary ~~screening~~ ~~of~~ ~~hits~~ against key viruses e.g. Hep B, infuenza, Zika, Ebola etc	Designed library of compounds to target viroporins: IniZally >250 compounds design~~ed~~ ~~and~~ ~~synthesised;~~ librarynow ~350 BIT314 (HCV) Compounds screened in proprietary assay set up for each virus target e.g. HIV-1 Vpu; HCV p7; Infuenza M2; Dengue M; Coronavirus E. Hits tested against ~~virus~~ ~~in~~ ~~cell~~ cultures Lead op,misa,on and selec,on OTHER “HITS” IN LIBRARY include: - Infuenza A and B - Coronaviruses ~~-~~ ~~Including~~ ~~SARS~~ - Epstein-Barr virus(EBV) - HepaZZs B virus (HBV) BIT225 is a representaZon of the value that resides within Biotron’s core experZse DENGUE – ~~Several~~ compounds with promising anZviral acZvity OTHERVIRUSES – Secondary ~~screening~~ ~~of~~ ~~hits~~ against key viruses e.g. Hep B, infuenza, Zika, Ebola etc	Designed library of compounds to target viroporins: IniZally >250 compounds design~~ed~~ ~~and~~ ~~synthesised;~~ librarynow ~350 BIT314 (HCV) Compounds screened in proprietary assay set up for each virus target e.g. HIV-1 Vpu; HCV p7; Infuenza M2; Dengue M; Coronavirus E. Hits tested against ~~virus~~ ~~in~~ ~~cell~~ cultures Lead op,misa,on and selec,on OTHER “HITS” IN LIBRARY include: - Infuenza A and B - Coronaviruses ~~-~~ ~~Including~~ ~~SARS~~ - Epstein-Barr virus(EBV) - HepaZZs B virus (HBV) BIT225 is a representaZon of the value that resides within Biotron’s core experZse DENGUE – ~~Several~~ compounds with promising anZviral acZvity OTHERVIRUSES – Secondary ~~screening~~ ~~of~~ ~~hits~~ against key viruses e.g. Hep B, infuenza, Zika, Ebola etc	Designed library of compounds to target viroporins: IniZally >250 compounds design~~ed~~ ~~and~~ ~~synthesised;~~ librarynow ~350 BIT314 (HCV) Compounds screened in proprietary assay set up for each virus target e.g. HIV-1 Vpu; HCV p7; Infuenza M2; Dengue M; Coronavirus E. Hits tested against ~~virus~~ ~~in~~ ~~cell~~ cultures Lead op,misa,on and selec,on OTHER “HITS” IN LIBRARY include: - Infuenza A and B - Coronaviruses ~~-~~ ~~Including~~ ~~SARS~~ - Epstein-Barr virus(EBV) - HepaZZs B virus (HBV) BIT225 is a representaZon of the value that resides within Biotron’s core experZse DENGUE – ~~Several~~ compounds with promising anZviral acZvity OTHERVIRUSES – Secondary ~~screening~~ ~~of~~ ~~hits~~ against key viruses e.g. Hep B, infuenza, Zika, Ebola etc	Designed library of compounds to target viroporins: IniZally >250 compounds design~~ed~~ ~~and~~ ~~synthesised;~~ librarynow ~350 BIT314 (HCV) Compounds screened in proprietary assay set up for each virus target e.g. HIV-1 Vpu; HCV p7; Infuenza M2; Dengue M; Coronavirus E. Hits tested against ~~virus~~ ~~in~~ ~~cell~~ cultures Lead op,misa,on and selec,on OTHER “HITS” IN LIBRARY include: - Infuenza A and B - Coronaviruses ~~-~~ ~~Including~~ ~~SARS~~ - Epstein-Barr virus(EBV) - HepaZZs B virus (HBV) BIT225 is a representaZon of the value that resides within Biotron’s core experZse DENGUE – ~~Several~~ compounds with promising anZviral acZvity OTHERVIRUSES – Secondary ~~screening~~ ~~of~~ ~~hits~~ against key viruses e.g. Hep B, infuenza, Zika, Ebola etc	Designed library of compounds to target viroporins: IniZally >250 compounds design~~ed~~ ~~and~~ ~~synthesised;~~ librarynow ~350 BIT314 (HCV) Compounds screened in proprietary assay set up for each virus target e.g. HIV-1 Vpu; HCV p7; Infuenza M2; Dengue M; Coronavirus E. Hits tested against ~~virus~~ ~~in~~ ~~cell~~ cultures Lead op,misa,on and selec,on OTHER “HITS” IN LIBRARY include: - Infuenza A and B - Coronaviruses ~~-~~ ~~Including~~ ~~SARS~~ - Epstein-Barr virus(EBV) - HepaZZs B virus (HBV) BIT225 is a representaZon of the value that resides within Biotron’s core experZse DENGUE – ~~Several~~ compounds with promising anZviral acZvity OTHERVIRUSES – Secondary ~~screening~~ ~~of~~ ~~hits~~ against key viruses e.g. Hep B, infuenza, Zika, Ebola etc
					OTHER “HITS” IN LIBRARY include: - Infuenza A and B - Coronaviruses ~~-~~ ~~Including~~ ~~SARS~~ - Epstein-Barr virus(EBV) - HepaZZs B virus (HBV)
Designed library of compounds to target viroporins: IniZally >250 compounds design~~ed~~ ~~and~~ ~~synthesised;~~ librarynow ~350
	~~d~~ ~~and~~ ~~synthesised;~~ ow ~350				- Epstein-Barr virus(EBV)
			its tested against		- HepaZZs B virus (HBV)

		DENGUE – ~~Sl~~	~~virus~~ ~~in~~ ~~cell~~ cultures OTHERVIRUSES –
				OTHERVIRUSES –

		~~evera~~ compounds		Secondary
		with promising anZviral acZvity		~~screening~~ ~~of~~ ~~hits~~ against key viruses e.g. Hep B, infuenza, Zika, Ebola etc
					BIT225 is a representaZon of the value that resides within Biotron’s core experZse

BIT225
(HIV-‐1
and
HCV)

==> picture [164 x 54] intentionally omitted <==

**BIT225

–
First
of
a
New
Class
of
HCV
DAA
Drugs**

POLYMERASE/PROTEASE INHIBITORS
e.g. Sofosbuvir/Simeprevir BIT225
-‐
ASSEMBLY/ BUDDING
INHIBITOR

ü Novel,
oral,
small
molecule
compound

ü Only
one
of
its
class
(p7
inhibitor)
in
clinical
trials

ü Inhibits
viral
assembly
and
infec,vity

ü Pan-‐genotype
ac,vity:

ü Ac,ve in
vitro against
all
main
genotypes

ü Clinically
ac,ve
against
hard-‐to-‐treat
HCV
GT 1
(1a
and
1b)
and
GT
3

==> picture [720 x 50] intentionally omitted <==

~~HCV market predicted to earn US$36 billion in 2018~~

• 180
million
infected
worldwide
(3%
world
popula,on)

• Recent
new
HCV
drug
combina,ons
are
good,
but
not
op,mal • Lengthy
treatment
–
12
weeks
or
more

• Not
pan-‐genotypic
– BIT225
is
pan-‐genotypic in
vitro

The
new
HCV
drugs
are
EXPENSIVE!!!
Very
large
markets
currently
untapped
ex-‐USA/Europe • 30
million
in
China

• Poten,al
for
another
class
of
DAA
such
as
BIT225: • Shorten
treatment
,mes
and
reduce
costs

Unmet
need
in
markets
within
Asia
region

==> picture [720 x 50] intentionally omitted <==

**HIV-‐1:

Towards
a
Cure**

==> picture [289 x 303] intentionally omitted <==

HIV-‐1
remains
hidden
in
reservoirs,
leading
to
chronic,
life-‐ long
infec,on
Invisible
to
body’s
immune
defenses
Not
sensi,ve
to
an,-‐HIV-‐1
drugs
Pa,ents
need
to
stay
on
an,retroviral
drugs
to
keep
virus levels
under
control
Long-‐term
health
implica,ons

New
drugs
are
needed
to
eradicate
or
cure
HIV-‐1
infec,on

BIT225
has
shown
clinical
efficacy
in
reducing
virus
levels in
reservoir
cells
Key
Phase
2
trial
anZcipated
to
commence
mid-‐2016

==> picture [720 x 38] intentionally omitted <==

Renewed
industry
interest
in
targe,ng
viral
diseases
including

Respiratory
syncy,al
virus
(RSV)
Hepa,,s
B
virus
Tropical
diseases
including
Dengue
Influenza
(in
par,cular
drug
resistant
strains)
Ebola
and
MERS-‐CoV
outbreaks
have
caused
public
health
issues
worldwide
BIT225
has
demonstrated
the
robustness
of
Biotron’s
approach
Compounds
with
ac,vity
against
other
key
viruses;
secondary
screening
is
in
progress;
aim
to iden,fying
candidates
to
progress
into
IND-‐enabling
studies
Seeking
partnerships
for
HIV-‐1
and
HCV
programs,
as
well
as
earlier
stage
programs,
in
par,cular within
Asian
region

**Dengue

Virus
Program**

2.5 billion people (40% world popula,on) live in areas at risk of
Dengue
~100
million
people
infected
yearly
A
leading
cause
of
illness
and
death
in
tropics
and
subtropics
Transmission
is
by
mosquito;
most
preven,on
programs target
the
vector

==> picture [255 x 125] intentionally omitted <==

No
approved
Dengue-‐specific
therapeu,c
drug
Vaccine
trials
have
had
disappoin,ng
results
Biotron
is
targe,ng
Dengue
M
protein
–
Similar
target
to HIV-‐1/Vpu
and
HCV/p7
Several
compounds
with
promising
ac,vity
have
been generated;
tests
are
on-‐going

==> picture [255 x 141] intentionally omitted <==

----- Start of picture text -----

www.sciencenews.org
----- End of picture text -----

==> picture [720 x 50] intentionally omitted <==

**Key

Financial
Metrics**

6
Month
Share
Price
Performance Ticker
Code ASX:
BIT Share
Price
(29/04/16) A
$0.063 Ticker
Code ASX:
BIT Market
cap A
$20
million Share
Price
(15
Sept
2014) A
$0.115 12
Month
Trading
Range A
$0.041
–
0.150 Market
cap A
$26.3
million Shares
Outstanding 313
million 12
Month
Trading
Range A
$0.075
–
0.315 Op,ons
(BITO) 50.7
million
$0.12
expiry
30/09/16 Shares
Outstanding 228
million Cash Posi,on (09/2015) Board A $4.7 million Cash
Posi,on
(06/14) A
$1.76mn ~~Michael Hoy Non-execu,ve Chairman~~ Michelle
Miller Managing
Director Susan
Pond Non-‐execu,ve
Director Rob
Thomas Non-‐execu,ve
Director Denis
Wade Non-‐execu,ve
Director

Dr
Michelle
Miller Managing
Director +61
412
313329 [email protected] www.biotron.com.au

==> picture [420 x 60] intentionally omitted <==

==> picture [720 x 50] intentionally omitted <==

AI assistant

BIOTRON LIMITED Investor Presentation 2016

64528_rns_2016-05-03_3f1df49c-fa96-4adc-851b-af12065041eb.pdf

PRESENTATION AT BIOTECH INVEST 2016

Enquiries

**Biotron’s

**BIT225

**HIV-‐1:

**Dengue

**Key

AI assistant

BIOTRON LIMITED — Investor Presentation 2016

64528_rns_2016-05-03_3f1df49c-fa96-4adc-851b-af12065041eb.pdf

PRESENTATION AT BIOTECH INVEST 2016

Enquiries

**Biotron’s

**BIT225

**HIV-­‐1:

**Dengue

**Key

More from BIOTRON LIMITED

BIOTRON LIMITED Investor Presentation 2016

**HIV-‐1: